lncRNA MIR4435‑2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF‑β1

Zhang,Hui; Meng,Hao; Huang,Xiaona; Tong,Wenting; Liang,Xiaoxin; Li,Junlong; Zhang,Changrong; Chen,Ming

doi:10.3892/ol.2019.10757

lncRNA MIR4435‑2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF‑β1

Authors:
- Hui Zhang
- Hao Meng
- Xiaona Huang
- Wenting Tong
- Xiaoxin Liang
- Junlong Li
- Changrong Zhang
- Ming Chen
View Affiliations

Affiliations: The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, Department of Urology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, Department of 2nd Neurology, Guangzhou Liwan District Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510145, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China
Published online on: August 16, 2019 https://doi.org/10.3892/ol.2019.10757
Pages: 4016-4021
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long noncoding (lnc) RNA MIR4435‑2HG is known to promote lung cancer; however, its role in prostate carcinoma (PCa) remains unknown. The aim of the current study was therefore to investigate the role of MIR4435‑2HG in PCa by detecting differential gene expression using quantitative PCR and ELISA kits. Furthermore, overexpression experiments were performed to analyze gene interactions and Transwell assays were used to analyze cell invasion and migration. The present study demonstrated that plasma levels of MIR4435‑2HG and transforming growth factor‑β1 (TGF‑β1) were significantly higher in patients with PCa compared with healthy controls. Furthermore, MIR4435‑2HG and TGF‑β1 plasma levels were positively correlated in patients with PCa, but not in healthy controls. The results from the follow‑up study suggested that MIR4435‑2HG was closely associated with patient survival. MIR4435‑2HG overexpression and treatment with TGF‑β1 promoted cancer cell invasion and migration. In addition, TGF‑β inhibitor attenuated the enhancing effects of MIR4435‑2HG overexpression on cell invasion and migration. MIR4435‑2HG overexpression led to upregulation of TGF‑β1 expression, whereas TGF‑β1 treatment had no effect on MIR4435‑2HG expression. These results suggested that MIR4435‑2HG may promote PCa by upregulating TGF‑β1.

View Figures

View References

1	Scher HI, Solo K, Valant J, Todd MB and Mehra M: Prevalence of prostate cancer clinical states and mortality in the United States: Estimates using a dynamic progression model. PLoS One. 10:e01394402015. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
5	Herrera FG, Tawadros T and Berthold DR: Bone metastases in prostate cancer: Pathophysiology, clinical complications, actual treatment, and future directions. Bone Cancer. Heymann D: 2nd. Elsevier; Amsterdam: pp. 657–663. 2015, View Article : Google Scholar
6	Massagué J and Chen YG: Controlling TGF-beta signaling. Genes Dev. 14:627–644. 2000.PubMed/NCBI
7	Akhurst RJ and Derynck R: TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001. View Article : Google Scholar : PubMed/NCBI
8	Derynck R, Muthusamy BP and Saeteurn KY: Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 31:56–66. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Tian XJ, Zhang H, Teng Y, Li R, Bai F, Elankumaran S and Xing J: TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal. 7:ra912014. View Article : Google Scholar : PubMed/NCBI
10	Wu W, Chen F, Cui X, Yang L, Chen J, Zhao J, Huang D, Liu J, Yang L, Zeng J, et al: LncRNA NKILA suppresses TGF-β-induced epithelial-mesenchymal transition by blocking NF-κB signaling in breast cancer. Int J Cancer. 143:2213–2224. 2018. View Article : Google Scholar : PubMed/NCBI
11	Gutschner T and Diederichs S: The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
12	Qian H, Chen L, Huang J, Wang X, Ma S, Cui F, Luo L, Ling L, Luo K and Zheng G: The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling. J Mol Med (Berl). 96:753–764. 2018. View Article : Google Scholar : PubMed/NCBI
13	Edge SB and Compton CC: The American Joint Committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hughes G: Youden's index and the weight of evidence. Methods Inf Med. 54:198–199. 2015. View Article : Google Scholar : PubMed/NCBI
16	Meulmeester E and Ten Dijke P: The dynamic roles of TGF-β in cancer. J Pathol. 223:206–218. 2011. View Article : Google Scholar
17	Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013. View Article : Google Scholar : PubMed/NCBI
18	Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, et al: The TGF-β signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell. 27:809–821. 2015. View Article : Google Scholar : PubMed/NCBI
19	Fan YH, Ji CX, Xu B, Fan HY, Cheng ZJ and Zhu XG: Long noncoding RNA activated by TGF-β in human cancers: A meta-analysis. Clin Chim Acta. 468:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
20	Li C, Wan L, Liu Z, Xu G, Wang S, Su Z, Zhang Y, Zhang C, Liu X, Lei Z and Zhang HT: Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. Cancer Lett. 418:185–195. 2018. View Article : Google Scholar : PubMed/NCBI
21	Nishita M, Hashimoto MK, Ogata S, Laurent MN, Ueno N, Shibuya H and Cho KW: Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer. Nature. 403:781–785. 2000. View Article : Google Scholar : PubMed/NCBI
22	Tuxhorn JA, McAlhany SJ, Yang F, Dang TD and Rowley DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 62:6021–6025. 2002.PubMed/NCBI
23	Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ and Kyprianou N: TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate. 79:31–43. 2019. View Article : Google Scholar : PubMed/NCBI